CTRL Therapeutics
- Industry
- Biotechnology
- Founded Year
- 2019
- Headquarters
- San Francisco, CA, USA
- Employee Count
- 20
Key People
- Derrell D. Porter, M.D. - Chief Executive Officer
- Shana Kelley, Ph.D. - Founder and Chief Technology Officer
- Rubn Alvarez Rodriguez - Head of Research
- Sosena W. - Head of Finance and Business Operations
- Cathy Ingrande - Executive Coordinator
- Collin Todd - Board Member
- Uma Lakshmipathy - Member, Scientific Advisory Board
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced biotech entrepreneurs and experts in cell therapy and technology development.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's potential for innovation and effective execution.
- Clinical Need
-
Aspect: Very Strong
Summary: CTRL Therapeutics addresses the significant challenge of treating solid tumors with cell therapy.
By developing a next-generation cell therapy platform for solid tumors, CTRL Therapeutics targets a pressing clinical need, potentially improving patient outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: The field of cell therapy for solid tumors has multiple players, but CTRL's approach offers differentiation.
The cell therapy market for solid tumors is competitive; however, CTRL's proprietary platform for isolating circulating tumor-reactive lymphocytes offers a novel approach that could distinguish it from competitors.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and validating a new cell therapy platform presents moderate technical challenges.
The process of isolating and expanding circulating tumor-reactive lymphocytes involves complex biological and engineering challenges, but the company's experienced team is well-equipped to address them.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents to protect its proprietary technology.
Securing patents for its technology would strengthen CTRL's market position and protect its innovations from competitors.
- Financing
-
Aspect: Well-funded
Summary: CTRL Therapeutics has secured $10 million in seed financing.
The $10 million seed round, led by reputable investors, enables the company to advance its research and development activities and expand its team.
- Regulatory
-
Aspect: Concept Stage
Summary: The company is in the early stages of development, with regulatory pathways yet to be defined.
Being at the concept stage, CTRL Therapeutics has the opportunity to design its development programs with regulatory considerations in mind from the outset, potentially streamlining future approval processes.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 4.9
- Segment CAGR
- 9.5%
- Market Segment
- Oncology
- Market Sub Segment
- Cell Therapy for Solid Tumors
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.25 |
| 2 | 0.74 |
| 3 | 1.72 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
CTRL Therapeutics is well-positioned to address a significant unmet need in oncology with its innovative cell therapy platform, supported by a strong team and solid initial funding.